Moreover, it has been recently reported that CDK4/6 axis is a tumor-intrinsic resistance mechanism to anti PD1 therapy in melanoma [70] and increased activity of the CDK4/6 inhibitor CDKN2A correlates with response to PD-L1 blockage in RCC and NSCLC patients [69]. The gene discussed is CDK4; the disease is neoplasm.